Is membranous location of EGFR or EGFRvIII immunostaining associated with good prognosis in renal cell carcinoma?

por Modjtahedi, H, Cunningham, M P
Publicado 2005

The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.

por Modjtahedi, H., Styles, J. M., Dean, C. J.
Publicado 1993

Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.

por Modjtahedi, H., Eccles, S., Box, G., Styles, J., Dean, C.
Publicado 1993

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells

por Ioannou, N, Dalgleish, A G, Seddon, A M, Mackintosh, D, Guertler, U, Solca, F, Modjtahedi, H
Publicado 2011

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10

por Modjtahedi, H, Khelwatty, S A, Kirk, R S, Seddon, A M, Essapen, S, Del Vecchio, C A, Wong, A J, Eccles, S
Publicado 2012

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.

por Modjtahedi, H., Hickish, T., Nicolson, M., Moore, J., Styles, J., Eccles, S., Jackson, E., Salter, J., Sloane, J., Spencer, L., Priest, K., Smith, I., Dean, C., Gore, M.
Publicado 1996